⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2024Open Access

Supplementary Material 1 from Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors

Ryan B. Corcoran T. Khanh Jeong Eun Kim James M. Cleary Aparna R. Parikh Oladapo Yeku Niya Xiong Colin D. Weekes Jennifer Veneris Leanne G. Ahronian Gianluca Mauri 俊彦上田 Bryanna L. Norden Alexa Michel Emily E. Van Seventer Giulia Siravegna Kyle Camphausen Gary Chi Isobel J. Fetter Joan S. Brugge Helen X. Chen Naoko Takebe Richard T. Penson Dejan Juric Keith T. Flaherty Ryan J. Sullivan Jeffrey W. Clark Rebecca S. Heist Ursula A. Matulonis Joyce F. Liu Geoffrey I. Shapiro

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Supplementary Table S1, Supplementary Table S2, Supplementary Figure S1

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Corcoran et al. (2024) studied this question.

synapsesocial.com/papers/68e6c4b3b6db6435876434a2 https://doi.org/10.1158/1078-0432.25728644.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Material 1 from Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors2024
2Data from Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors2024
3Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors2024 · 40 citations
4Supplementary Figure S1 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)2024
5Supplementary Figure S1 from Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)2024

More related papers

Supplementary File 2 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer2024
Supplementary File 2 from Vincristine Enhances the Efficacy of MEK Inhibitors in Preclinical Models of KRAS-mutant Colorectal Cancer2024
Supplementary Data 1 from Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors2024